CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CPH - CA17253X1050 - Common Stock
14.63 CAD
-0.06 (-0.41%)
Overall CPH gets a fundamental rating of 7 out of 10. We evaluated CPH against 32 industry peers in the Pharmaceuticals industry. CPH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPH is growing strongly while it is still valued neutral. This is a good combination! With these ratings, CPH could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year CPH was profitable.
CPH had a positive operating cash flow in the past year.
In the past 5 years CPH has always been profitable.
Each year in the past 5 years CPH had a positive operating cash flow.
1.2 Ratios
CPH's Return On Assets of 11.77% is amongst the best of the industry. CPH outperforms 93.75% of its industry peers.
The Return On Equity of CPH (15.23%) is better than 90.63% of its industry peers.
The Return On Invested Capital of CPH (7.23%) is better than 90.63% of its industry peers.
CPH had an Average Return On Invested Capital over the past 3 years of 8.42%. This is in line with the industry average of 8.14%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROIC | 7.23% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
1.3 Margins
With an excellent Profit Margin value of 34.68%, CPH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of CPH has grown nicely.
With an excellent Operating Margin value of 25.51%, CPH belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
In the last couple of years the Operating Margin of CPH has declined.
CPH has a Gross Margin of 74.32%. This is amongst the best in the industry. CPH outperforms 93.75% of its industry peers.
CPH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% |
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
CPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, CPH has more shares outstanding
CPH has less shares outstanding than it did 5 years ago.
CPH has a worse debt/assets ratio than last year.
2.2 Solvency
CPH has an Altman-Z score of 6.32. This indicates that CPH is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CPH (6.32) is better than 93.75% of its industry peers.
The Debt to FCF ratio of CPH is 0.45, which is an excellent value as it means it would take CPH, only 0.45 years of fcf income to pay off all of its debts.
CPH has a better Debt to FCF ratio (0.45) than 93.75% of its industry peers.
CPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.12, CPH is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Altman-Z | 6.32 |
ROIC/WACC0.86
WACC8.38%
2.3 Liquidity
A Current Ratio of 1.30 indicates that CPH should not have too much problems paying its short term obligations.
CPH has a worse Current ratio (1.30) than 62.50% of its industry peers.
A Quick Ratio of 0.98 indicates that CPH may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.98, CPH is in line with its industry, outperforming 40.63% of the companies in the same industry.
The current and quick ratio evaluation for CPH is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
CPH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.76%.
Measured over the past years, CPH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.97% on average per year.
The Revenue has grown by 89.17% in the past year. This is a very strong growth!
Measured over the past years, CPH shows a quite strong growth in Revenue. The Revenue has been growing by 8.25% on average per year.
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
3.2 Future
The Earnings Per Share is expected to grow by 20.66% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 27.91% on average over the next years. This is a very strong growth
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.08 indicates a correct valuation of CPH.
Based on the Price/Earnings ratio, CPH is valued cheaper than 81.25% of the companies in the same industry.
CPH is valuated rather cheaply when we compare the Price/Earnings ratio to 26.92, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 17.06, the valuation of CPH can be described as rather expensive.
CPH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CPH is cheaper than 71.88% of the companies in the same industry.
CPH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.08 | ||
| Fwd PE | 17.06 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CPH.
Based on the Price/Free Cash Flow ratio, CPH is valued a bit cheaper than the industry average as 78.13% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.98 | ||
| EV/EBITDA | 13.89 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPH has an outstanding profitability rating, which may justify a higher PE ratio.
CPH's earnings are expected to grow with 20.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)1.24
EPS Next 2Y16.2%
EPS Next 3Y20.66%
5. Dividend
5.1 Amount
No dividends for CPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:CPH (1/7/2026, 7:00:00 PM)
14.63
-0.06 (-0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners1.29%
Inst Owner ChangeN/A
Ins Owners3.62%
Ins Owner ChangeN/A
Market Cap371.16M
Revenue(TTM)50.05M
Net Income(TTM)17.36M
Analysts77.5
Price Target18.39 (25.7%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.24%
Min EPS beat(2)36.14%
Max EPS beat(2)66.34%
EPS beat(4)2
Avg EPS beat(4)14.52%
Min EPS beat(4)-37.21%
Max EPS beat(4)66.34%
EPS beat(8)5
Avg EPS beat(8)34.73%
EPS beat(12)9
Avg EPS beat(12)113.55%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-6.01%
Max Revenue beat(2)2.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-6.01%
Max Revenue beat(4)2.48%
Revenue beat(8)2
Avg Revenue beat(8)-0.16%
Revenue beat(12)3
Avg Revenue beat(12)1.53%
Revenue beat(16)3
Avg Revenue beat(16)-1.19%
PT rev (1m)0%
PT rev (3m)2.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.59%
Revenue NQ rev (1m)0.79%
Revenue NQ rev (3m)-5.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.08 | ||
| Fwd PE | 17.06 | ||
| P/S | 5.37 | ||
| P/FCF | 8.98 | ||
| P/OCF | 8.96 | ||
| P/B | 2.36 | ||
| P/tB | 11.77 | ||
| EV/EBITDA | 13.89 |
EPS(TTM)0.91
EY6.22%
EPS(NY)0.86
Fwd EY5.86%
FCF(TTM)1.63
FCFY11.13%
OCF(TTM)1.63
OCFY11.16%
SpS2.72
BVpS6.2
TBVpS1.24
PEG (NY)0.31
PEG (5Y)1.24
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| ROCE | 10.05% | ||
| ROIC | 7.23% | ||
| ROICexc | 7.75% | ||
| ROICexgc | 33.36% | ||
| OM | 25.51% | ||
| PM (TTM) | 34.68% | ||
| GM | 74.32% | ||
| FCFM | 59.76% |
ROA(3y)22.3%
ROA(5y)18.43%
ROE(3y)26.05%
ROE(5y)22.41%
ROIC(3y)8.42%
ROIC(5y)14.92%
ROICexc(3y)14.84%
ROICexc(5y)25.78%
ROICexgc(3y)32.35%
ROICexgc(5y)N/A
ROCE(3y)11.69%
ROCE(5y)20.72%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-55.02%
ROICexc growth 5Y-33.6%
OM growth 3Y-26.62%
OM growth 5Y-14.41%
PM growth 3Y-0.73%
PM growth 5Y19.11%
GM growth 3Y-4.61%
GM growth 5Y-3.67%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.45 | ||
| Debt/EBITDA | 0.67 | ||
| Cap/Depr | 1.2% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 152.24% | ||
| Profit Quality | 172.34% | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z | 6.32 |
F-Score7
WACC8.38%
ROIC/WACC0.86
Cap/Depr(3y)670.82%
Cap/Depr(5y)415.05%
Cap/Sales(3y)80.33%
Cap/Sales(5y)48.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.76%
EPS 3Y14.06%
EPS 5Y12.97%
EPS Q2Q%2000%
EPS Next Y51.5%
EPS Next 2Y16.2%
EPS Next 3Y20.66%
EPS Next 5YN/A
Revenue 1Y (TTM)89.17%
Revenue growth 3Y14.99%
Revenue growth 5Y8.25%
Sales Q2Q%23.75%
Revenue Next Year50.96%
Revenue Next 2Y26.89%
Revenue Next 3Y27.91%
Revenue Next 5YN/A
EBIT growth 1Y29.19%
EBIT growth 3Y-15.61%
EBIT growth 5Y-7.36%
EBIT Next Year138.56%
EBIT Next 3Y50.46%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y99.32%
OCF growth 3Y12.28%
OCF growth 5Y19.77%
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the ChartMill fundamental rating of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA.
What is the valuation status for CPH stock?
ChartMill assigns a valuation rating of 6 / 10 to CIPHER PHARMACEUTICALS INC (CPH.CA). This can be considered as Fairly Valued.
What is the profitability of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
The Price/Earnings (PE) ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 16.08 and the Price/Book (PB) ratio is 2.36.
How financially healthy is CIPHER PHARMACEUTICALS INC?
The financial health rating of CIPHER PHARMACEUTICALS INC (CPH.CA) is 7 / 10.